Amlodipine(ADP) antibody/antigen (BSA/OVA/KLH conjugated hapten)
anti-Amlodipine(ADP) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)
Go to Drugs of Abuse diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-208-1 | 1. BSA-Amlodipine(ADP) 2. Anti-Amlodipine(ADP) mouse monoclonal antibody | $2709.00 |
GMP-SMT-208-2 | 1. OVA-Amlodipine(ADP) 2. Anti-Amlodipine(ADP) mouse monoclonal antibody | $2709.00 |
GMP-SMT-208-3 | 1. BSA-Amlodipine(ADP) 2. Anti-Amlodipine(ADP) human monoclonal antibody | $2709.00 |
GMP-SMT-208-4 | 1. OVA-Amlodipine(ADP) 2. Anti-Amlodipine(ADP) human monoclonal antibody | $2709.00 |
GMP-SMT-208-Ag-1 | BSA-Amlodipine(ADP) | $756.00 |
GMP-SMT-208-Ag-2 | OVA-Amlodipine(ADP) | $756.00 |
GMP-SMT-208-Ab-1 | Anti-Amlodipine(ADP) mouse monoclonal antibody | $1953.00 |
GMP-SMT-208-Ab-2 | Anti-Amlodipine(ADP) human monoclonal antibody | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
BSA-Amlodipine(ADP)
Cat No. | GMP-SMT-208-Ag-1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Amlodipine(ADP) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Amlodipine(ADP) had been validated with our anti-Hapten antibody Anti-Amlodipine(ADP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
OVA-Amlodipine(ADP)
Cat No. | GMP-SMT-208-Ag-2 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates OVA-Amlodipine(ADP) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Amlodipine(ADP) had been validated with our anti-Hapten antibody Anti-Amlodipine(ADP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Amlodipine(ADP) mouse monoclonal antibody
Cat No. | GMP-SMT-208-Ab-1 |
Host of Antibody | Mouse IgG |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 2-2.5 |
Products description | The anti-Hapten antibody against hapten Amlodipine(ADP) had been validated with our hapten hapten-carrier conjugates BSA-Amlodipine(ADP) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Amlodipine(ADP) human monoclonal antibody
Cat No. | GMP-SMT-208-Ab-2 |
Host of Antibody | Human IgG1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 2-2.5 |
Products description | The anti-Hapten antibody against hapten Amlodipine(ADP) had been validated with our hapten hapten-carrier conjugates BSA-Amlodipine(ADP) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Biomarker Information
1. Amlodipine (ADP): An In-Depth Exploration and Its Integral Role in In Vitro Diagnosis (IVD)
Serial number 1 delves into the comprehensive understanding of Amlodipine (ADP), a dihydropyridine calcium channel blocker belonging to the category of small molecules. Within the context of in vitro diagnosis (IVD), Amlodipine emerges as a crucial component, offering distinctive features and applications. To elucidate further:
Amlodipine (ADP) Unveiled:
Amlodipine, designated under serial number 1, is a representative member of the dihydropyridine class of calcium channel blockers. This small molecule exerts its therapeutic effects by selectively inhibiting the influx of calcium ions into vascular smooth muscle cells and cardiac myocytes. Clinically, Amlodipine is widely employed for the treatment of hypertension and angina pectoris, contributing to its prominence in the pharmaceutical landscape.
Amlodipine in In Vitro Diagnosis (IVD):
Now, turning our attention to its role in in vitro diagnosis (IVD), Amlodipine assumes an indispensable role. Specifically, Amlodipine serves as a competitive antigen within immunoassays, where it is often conjugated with carrier molecules like Bovine Serum Albumin (BSA) or Ovalbumin (OVA). This conjugation facilitates its effective utilization in diagnostic tests and research endeavors.
2. Significance of Amlodipine (ADP) Measurement in IVD
Serial number 2 pivots toward understanding the importance of measuring Amlodipine (ADP) within the sphere of in vitro diagnosis, emphasizing its clinical and scientific significance.
A Crucial Therapeutic Agent:
Amlodipine's clinical utility stems from its role as a potent antihypertensive and antianginal agent. It achieves this by inhibiting calcium ion influx into vascular smooth muscle cells, ultimately leading to vasodilation and reduced cardiac workload. Given its widespread use in managing cardiovascular conditions, precise monitoring of Amlodipine levels in patient samples is paramount to ensure therapeutic efficacy and safety.
In Vitro Diagnosis (IVD) Advancements:
Beyond its clinical application, Amlodipine's value extends to the realm of in vitro diagnosis (IVD). Immunoassays, a cornerstone of modern diagnostics, rely on the interaction between antigens and antibodies for the detection of specific molecules. Amlodipine, when used as a competitive antigen, enhances the accuracy and sensitivity of immunoassays designed to detect Amlodipine in patient samples. By conjugating Amlodipine with carrier molecules such as BSA or OVA, researchers and diagnosticians can develop highly specific and reliable tests for the quantification of Amlodipine. This technological advancement plays a pivotal role in the accurate diagnosis and management of cardiovascular conditions, ultimately benefiting patient care.
The Intersection of Clinical Practice and Research:
In summary, Amlodipine (ADP) occupies a pivotal position within the healthcare landscape, both in clinical practice and scientific research. Its dual role as a therapeutic agent for hypertension and angina, along with its utility as a competitive antigen in immunoassays, underscores its significance. Precise measurement of Amlodipine levels not only ensures optimal patient care but also propels the development of advanced diagnostic tools, contributing to the ever-evolving field of in vitro diagnosis. As we continue to explore the multifaceted applications of Amlodipine, its importance in healthcare and scientific advancements becomes increasingly apparent.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.